Avantium Technologies B.V.

Avantium to Deliver Flowrence(TM) Systems to Shell

    Amsterdam (ots/PRNewswire) - Avantium Technologies announced today that they have signed an agreement with CRI/Criterion Inc. to enable the sale and delivery of multiple Avantium Flowrence(TM) systems.

    CRI/Criterion, a catalyst technology company within the Royal Dutch Shell group, is a part of a group of affiliated companies that are leading providers of catalysts, process technologies and catalyst services for a wide range of chemical and refinery applications. Under the agreement Avantium will sell and deliver Flowrence(TM) Research platforms to CRI/Criterion or its affiliates to enhance its research capabilities.

    Tom van Aken, Chief Executive Officer of Avantium:" We are pleased to provide our unique Flowrence(TM) technology to Shell. The sale of Flowrence(TM) platforms to a world leading company such as Shell is a recognition of the value of our proprietary high-throughput R&D technology. These systems allow our customers to significantly increase their R&D productivity."

    Flowrence(TM) is a proprietary system developed by Avantium for catalysis research. It consists of a parallel fixed bed reactor system with 16 reactors suited for gas and liquid phase, as well as trickle flow operation. Flowrence(TM) enables users to test catalytic materials for a range of chemistries under industrial processing conditions, including high-temperature and high-pressure reactions.

    Profile Avantium

    Avantium is a leading technology company in the area of advanced high-throughput R&D operating in the energy, chemicals and pharmaceutical industries. The company develops products and processes in the area of biofuels, bio-based chemicals and novel crystal forms of existing drugs by applying its proprietary, high-throughput R&D technology. Avantium has demonstrated the potential of this technology by providing R&D services and tools to more than 70 companies worldwide, including many of the world's largest energy, chemicals and pharmaceutical companies. Avantium has approximately 100 employees; its offices and head quarters are based in Amsterdam, the Netherlands.

    Flowrence(TM)

    For more information about Flowrence(TM), including downloads and pictures, please visit http://www.flowrence.com or http://www.avantium.com.  Flowrence(TM) is a trademark of Avantium Technologies B.V.

    Visit Avantium's corporate website at: http://www.avantium.com

    Other Information

    This release may contain certain forward-looking statements relating to the business, financial performance and results of Avantium and the industry in which it operates. These statements are based on its current plans, estimates and projections, as well as its expectations of external conditions and events. A number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements.

    In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

ots Originaltext: Avantium Technologies B.V.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
For more information about this press release please contact us via:
Citigate First Financial, Jose Tijssen / Claire Verhagen, Phone:
+31-20-575-4010, Email: Jose.Tijssen@citigateff.nl /
Claire.Verhagen@citigateff.nl



Weitere Meldungen: Avantium Technologies B.V.

Das könnte Sie auch interessieren: